We have discovered that neutral β1,3 glucan and nucleic acids (currently homologous sequences such as poly(dA)) bind to two glucose molecules in the main chain of sugar and one base of nucleic acid to form a high-molecular-weight complex consisting of two saccharide chains and one nucleic acid chain [1, 2]. This complex is recognized by Dectin 1, a receptor for β1,3 glucan, which is mainly expressed in immune cells, and is taken up into the cells [3]. We are aiming to apply this property for the delivery of CpG motif to antigen-presenting cells as a vaccine adjuvant [4] and for the treatment of various diseases by suppressing immune system molecules such as CD40 using RNA interference [5]. In 2004, we established a venture company, NapaJen, based on this polysaccharide nucleic acid complex, and after a corporate acquisition during the Corona disaster, we are now aiming to commercialize our purely domestic DDS technology as Immunohelix.